Home | Welcome to Contract Pharma   
Last Updated Saturday, October 25 2014
Print RSS Feed

Dr. Reddy's Expands CPS Business



Published October 8, 2012
Related Searches: Manufacturing Development cGMP Preclinical
The Custom Pharmaceutical Services (CPS) business of Dr. Reddy’s Laboratories has expanded operations at its facility in Mirfield, UK in the areas of activated mPEG manufacturing and the development and manufacture of NCE APIs for preclinical through to commercial development.
 
The expansion enables the manufacture of its PEGtech range at commercial metric ton scale quantities in a cGMP environment. Dr. Reddy’s has eight API manufacturing facilities, six FDA-approved plants in India, one FDA-approved plant in Mexico, and one FDA-approved plant in Mirfield, UK.
 
Dr. R. Ananthanarayanan, president of the Pharmaceutical Services and Active Ingredients business of Dr. Reddy’s said, “This expansion builds on our commitment to expand operations in UK and provide a superior network of cGMP manufacturing to support our global customer base. PEGylation is one area where we felt the need for expanding our capabilities. We have invested in multiple technology areas and the expansion will add significant value in the areas of mPEGs and cGMP API manufacturing.”
 


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On